hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06310499, orgStudyIdInfo id: DROWN_COD, briefTitle: Primary or Secondary Drowning, acronym: DROWN_COD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Prehospital Center, Region Zealand, class: OTHER, descriptionModule briefSummary: According to WHO's rules, any death certificate must state the underlying cause of death and contributory causes of death may also be stated.Differentiating between primary and secondary drowning is difficult, as information preceding the drowning incident is rarely available. Yet, knowing the most frequent causes of secondary drowning may provide useful information to healthcare professionals working in prehospital Emergency Medical Services, as this may affect prehospital treatment., conditionsModule conditions: Drowning, conditions: Drowning; Anoxia, conditions: Drowning, Near, conditions: Drowning in Swimming Pool, conditions: Drowning; Asphyxia, conditions: Drowning/Diving/SCUBA Accident, conditions: Drowning or Immersion of Unknown Intent, conditions: Drowning and Submersion, Undetermined Intent, conditions: Drowning and Submersion While in Bath-Tub, conditions: Drowning and Submersion While in Natural Water, conditions: Drowning and Submersion Due to Sailboat Sinking, conditions: Drowning and Submersion Due to Fall Off Ship, conditions: Drowning and Submersion While in Swimming-Pool, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 700, type: ESTIMATED, armsInterventionsModule interventions name: Drowning, outcomesModule primaryOutcomes measure: Autopsy rate, primaryOutcomes measure: Primary fatal drowning rate, primaryOutcomes measure: Secondary fatal drowning rate, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Prehospital Center, city: Næstved, state: Region Zealand, zip: 4700, country: Denmark, geoPoint lat: 55.22992, lon: 11.76092, hasResults: False
protocolSection identificationModule nctId: NCT06310486, orgStudyIdInfo id: DROWN_CALL, briefTitle: The Emergency Call on Drowning, acronym: DROWN_CALL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Prehospital Center, Region Zealand, class: OTHER, descriptionModule briefSummary: This study aims to 1) describe patient-, setting-, and dispatcher-related characteristics in drowning-related emergency calls to the Emergency Medical Dispatch Centre (1-1-2 emergency phone) and 2) factors associated with 30-day survival. The investigators will separately analyse drowning-related out-of-hospital cardiac arrest (OHCA) and drowning-related non-OHCA. If feasible, the investigators will qualitatively analyse the calls to identify and describe potential barriers for an optimal handling strategy., conditionsModule conditions: Drowning, conditions: Drowning; Anoxia, conditions: Drowning, Near, conditions: Drowning; Asphyxia, conditions: Drowning and Nonfatal Submersion, conditions: Drowning or Immersion of Unknown Intent, conditions: Drowning and Submersion, Undetermined Intent, conditions: Drowning and Submersion While in Bath-Tub, conditions: Drowning and Submersion While in Natural Water, conditions: Drowning and Submersion Due to Sailboat Sinking, conditions: Drowning and Submersion Due to Fall Off Ship, conditions: Drowning and Submersion While in Swimming-Pool, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1500, type: ESTIMATED, armsInterventionsModule interventions name: Drowning-related OHCA, interventions name: Drowning-related non-OHCA, outcomesModule primaryOutcomes measure: Patient-related characteristics influencing the 30-day survival, primaryOutcomes measure: Setting-related characteristics influencing the 30-day survival, primaryOutcomes measure: Caller-related characteristics influencing the 30-day survival, primaryOutcomes measure: Dispatcher-related characteristics influencing the 30-day survival, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Prehospital Center, city: Næstved, state: Region Zealand, zip: 4700, country: Denmark, geoPoint lat: 55.22992, lon: 11.76092, hasResults: False
protocolSection identificationModule nctId: NCT06310473, orgStudyIdInfo id: NFEC-2023-582, briefTitle: Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Nanfang Hospital, Southern Medical University, class: OTHER, descriptionModule briefSummary: For locally advanced esophagogastric junction and gastric cancer, neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early, and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate.Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer., conditionsModule conditions: Gastric Cancer, conditions: Esophagogastric Junction Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cadonilimab, interventions name: Oxaliplatin, interventions name: Capecitabine, outcomesModule primaryOutcomes measure: Pathologic complete remission rate (pCR), secondaryOutcomes measure: Major pathologic response，MPR, secondaryOutcomes measure: R0 resection rate, secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: 3-year disease-free survival rate of 3year (DFS), secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanfang Hospital, Southern Medical University, city: Guangzhou, state: Guangdong, zip: 510-515, country: China, contacts name: Guoxin Li, M.D., Ph.D., role: CONTACT, phone: +86-138-0277-1450, email: gzliguoxin@163.com, contacts name: Guoxin Li, M.D., Ph.D., role: PRINCIPAL_INVESTIGATOR, contacts name: Liying Zhao, M.D., Ph.D., role: SUB_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06310460, orgStudyIdInfo id: PCP, briefTitle: Evaluation of "PreCut-Papillectomy" in Difficult Biliary Cannulation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Kliniken Ludwigsburg-Bietigheim gGmbH, class: OTHER, descriptionModule briefSummary: To evaluate the effectiveness and sefety of papillectomy to enable bile duct access during endoscopic retrograde cholangiography in patients with difficult biliary cannulation., conditionsModule conditions: Cholangiopancreatography, Endoscopic Retrograde, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Papillectomy, outcomesModule primaryOutcomes measure: Rate of treatment success, primaryOutcomes measure: Adverse event rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310447, orgStudyIdInfo id: IstanbulBUFC2, briefTitle: Determination of Ecological Awareness and Attitudes Levels of Undergraduate Physiotherapy Students in Istanbul, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-03, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Istanbul Bilgi University, class: OTHER, descriptionModule briefSummary: The natural environment, which is the living environment of all living things; Technological advances and industrialization activities are being affected more and more negatively every day. Increasing energy demand and resource consumption due to population growth lead to negative consequences on ecological balance, such as environmental pollution, climate change and loss of natural environments. Health services have also increased resource use with the advancement of technology and caused negative effects on the environment. Health services have been slow to understand their impact on the environment. The aim of the study is to determine the environmental awareness and environmental attitude levels of physiotherapy and rehabilitation department students, to popularize the field of "Environmental Physiotherapy" and to enable the training of physiotherapist candidates with high environmental awareness., conditionsModule conditions: Ecological and Environmental Concepts, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 151, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Ecological Footprint Awareness Scale, primaryOutcomes measure: Environmental Awareness Scale, primaryOutcomes measure: Environmental Attitude Scale, secondaryOutcomes measure: Participant Information Form, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Istanbul Bilgi University, city: Istanbul, zip: 34440, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06310408, orgStudyIdInfo id: 0214022024, briefTitle: Comparison Between Nasal Mask vs Nasal Prong on Pain Response in Neonate, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Indonesia University, class: OTHER, descriptionModule briefSummary: to determine the comparison of nasal masks and nasal prongs on the pain response of neonate, conditionsModule conditions: Nasal Mask, conditions: Nasal Prong, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 1 group give nasal mask1 group give nasal prong, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: nasal mask, interventions name: nasal prong, outcomesModule primaryOutcomes measure: pain response, eligibilityModule sex: ALL, minimumAge: 26 Weeks, maximumAge: 44 Weeks, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310395, orgStudyIdInfo id: AMI_H.MAR, briefTitle: Analysis of the Acute Mesenteric Ischemia in a Single Institution Over 10 Years, acronym: AMI_HMAR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-15, primaryCompletionDateStruct date: 2024-07-15, completionDateStruct date: 2024-10-15, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Hospital del Mar, class: OTHER, descriptionModule briefSummary: Acute mesenteric ischemia (AMI) is a notorious disease with a high mortality, the diagnostic and management is truly multidisciplinary, and the aim of this study is to analyse the results of the patients admited with an AMI in Hospital de Mar., conditionsModule conditions: Acute Mesenteric Ischemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06310382, orgStudyIdInfo id: GH55-CRS001, briefTitle: A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-07, primaryCompletionDateStruct date: 2025-05-26, completionDateStruct date: 2025-08-04, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Suzhou Genhouse Bio Co., Ltd., class: OTHER, collaborators name: Shanghai East Hospital, collaborators name: Shandong Tumor Hospital, descriptionModule briefSummary: This is a multi-center, open-label, dose escalation phase I and dose expansion phase II study aimed to evaluate the safety, tolerability, PK and PD profiles as well as to observe the efficacy of GH55 in patients with MAPK mutant advanced solid tumors.This study is divided into two parts, namely the dose escalation phase I study and the dose expansion phase II study., conditionsModule conditions: Advanced Solid Tumors With MAPK Signal Pathway Mutant, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: GH55, outcomesModule primaryOutcomes measure: Number of participants with dose limiting toxicities, primaryOutcomes measure: Number of participants with adverse events, primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Number of participants with adverse events, secondaryOutcomes measure: Plasma concentration (Cmax), secondaryOutcomes measure: Time to achieve Cmax (Tmax), secondaryOutcomes measure: Area under the plasma concentration-time curve (AUC), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai East Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200120, country: China, contacts name: JIN LI, DOCTORATE, role: CONTACT, phone: 021-38804518, email: lijin@csco.org.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06310369, orgStudyIdInfo id: EORTC 2335-GUCG, briefTitle: Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-03-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2030-03-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: European Organisation for Research and Treatment of Cancer - EORTC, class: NETWORK, descriptionModule briefSummary: We aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has yet to be fully explored., conditionsModule conditions: Bladder Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: radiation therapy, outcomesModule primaryOutcomes measure: Proportion of patients with a CR at 6 months post-radiotherapy, secondaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: overall survival, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310343, orgStudyIdInfo id: 304993, briefTitle: ADAs to Alemtuzumab, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-04-25, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Queen Mary University of London, class: OTHER, descriptionModule briefSummary: The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24 months period, conditionsModule conditions: Multiple Sclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule interventions name: Alemtuzumab, outcomesModule primaryOutcomes measure: To quantify the longitudinal changes in alemtuzumab ADAs, secondaryOutcomes measure: 1. Relative occurrence of infusion-related reactions based on high alemtuzumab ADA levels prior to course 2., secondaryOutcomes measure: 2. Relative change in lymphocyte counts after the second infusion of alemtuzumab in ADA positive patients to assess the health economic impact of infusion-related reactions., secondaryOutcomes measure: 3. Relative change in relapses or EDSS score based on alemtuzumab ADA levels to assess the health economic impact of disease activity., secondaryOutcomes measure: 4. Relative change in relapses or EDSS score based on alemtuzumab ADA levels, secondaryOutcomes measure: 5. Relative change in T2 lesion number or Gd-enhancing lesions, and serum NfL based on alemtuzumab ADA levels to assess the health economic impact of disease activity., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Barts Health NHS Trust, city: London, state: Second Floor Neurophys Dept, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06310330, orgStudyIdInfo id: 2019/1059, briefTitle: TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography, acronym: TRUST-ACE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Norwegian University of Science and Technology, class: OTHER, collaborators name: St. Olavs Hospital, descriptionModule briefSummary: TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice., conditionsModule conditions: Breast Neoplasm Malignant Primary, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomization 1:1 to two different modes of follow-up, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, maskingDescription: No masking, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Comprehensive echocardiographic follow-up, interventions name: Simplified echocardiographic follow-up, outcomesModule primaryOutcomes measure: Proportion of patients correctly classified with cancer therapy related cardiac dysfunction (CTRCD), otherOutcomes measure: Proportion of patients misclassified as having/not having cancer therapy related cardiac dysfunction (CTRCD), otherOutcomes measure: Risk classification, otherOutcomes measure: Risk classification, otherOutcomes measure: Test-retest variability, systolic left ventricular size and function, otherOutcomes measure: Test-retest variability, systolic left ventricular size and function, otherOutcomes measure: Test-retest variability, diastolic left ventricular size and function, otherOutcomes measure: Test-retest variability, diastolic left ventricular size and function, otherOutcomes measure: Test-retest variability, right ventricular size and function, otherOutcomes measure: Test-retest variability, right ventricular size and function, otherOutcomes measure: Time consumption, otherOutcomes measure: Time consumption, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St. Olavs hospital, status: RECRUITING, city: Trondheim, zip: 7491, country: Norway, contacts name: Rune Wiseth, MD, PhD, role: CONTACT, phone: 92247845, phoneExt: 47, email: rune.wiseth@stolav.no, geoPoint lat: 63.43049, lon: 10.39506, hasResults: False